GLP-1 agonists inhibit TNF- and nuclear factor-kappa B (NF-B), thereby reducing pro-inflammatory cytokines
The more body weight a participant lost, the greater the improvement in body composition
The brand's own FAQ content also states that some therapies aren't appropriate during pregnancy or while trying to conceive, and that progress is tracked over time through symptom check-ins and, where relevant, biomarker tracking - with the plan adjusted based on how you respond
But I realize its intimidating, so heres the simple version: GLP-1RAs decrease neuroinflammation GLP-1RAs improve amyloid clearance GLP-1RAs decrease amyloid production by inhibiting BACE1 If toxic amyloid were cupcakes, BACE1 is the cupcake tin
Over time, its also been studied for its potential effects on: Stress regulation Cortisol levels Pain perception Withdrawal symptoms That last point is whats driving interest in addiction and recovery spaces today
For a medication to reach NHS patients, it needs to clear three stages: MHRA marketing authorisation